Yingjie Hu received her Bachelor and Master degree in Pharmaceutical Sciences at Peking University, China. She currently is in the second year of her PhD in Department of Chemical Engineering at the University of Melbourne. She is also working as an Education committee member in the ARC Centre of Excellence in Convergent Bio-Nano Science & Technology (CBNS).
Upon years of study in biomedical technology, Yingjie has developed a strong research interest in nano-system, bio-nano interaction and cancer therapy. Her previous projects during her Master-degree study mainly focused on nanoscale liposomal drug delivery systems for heterogeneous breast cancer therapy. Currently, her PhD projects focus on nanoscale antibody particles and their interactions with biological systems including cancer cells and cellular receptors, human blood and animals. In addition to her academic studies, she has gained some industry internship experience in pharmaceutical companies (MSD and Pfizer) during her Bachelor and Mater study in China, which inspired her to learn more about pharmaceutical industry field and cutting-edge industry-academia collaboration.